Endo’s buy of struggling Auxilium for $2.6 billion analysed by GlobalData

12 October 2014

Endo International’s (Nasdaq: ENDP) $2.6 billion purchase of Auxilium Pharmaceuticals (Nasdaq: AUXL; The Pharma Letter October 9) complements Endo’s urology and male health portfolio, and the company intends to leverage its resources to optimize and drive increased adoption of three key Auxilium drugs, according to an analyst with research and consulting firm GlobalData.

Adam Dion, GlobalData’s analyst covering health care industry dynamics, identifies these treatments as Xiaflex (clostridial collagenase for injection), approved for the treatment of Dupuytren’s contracture and Peyronie’s disease, and Auxilium’s Testopel and Testim, both hormone replacement agents.

NPV of Auxilium pharma assets put at $2.5 billion

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK